Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Announces Terms for $100 Million US IPO; Starts China Trial of Immunoncology Drug

publication date: Jan 3, 2020

I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares at a price that ranges from $12 to $15. Final pricing is expected on January 16. In addition, I-Mab has dosed the first patient in a registrational China Phase II trial of a CD38 antibody in patients with relapsed-refractory multiple myeloma (MM). In 2017, I-Mab in-licensed greater China rights to the antibody from Germany's MorphoSys. More details....

Stock Symbol: (FSE: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.